Wednesday, May 22, 2024
HomeEconomyIs there a CEA study for most Medicare Part D drugs? –...

Is there a CEA study for most Medicare Part D drugs? – Healthcare economist

This is the question raised by a recent study Teesdale et al. (2021) Designed to answer. They first checked the 2016 medical insurance Part D drugs of the top 250 medical insurance Part D drugs based on the 2016 medical insurance Part D prescription drugs.Drug characteristics determined from 2016 FDA Orange BookThe authors used data from the United States to determine whether a drug has undergone a related cost-benefit analysis (CEA) study. Tufts Medical Center Cost-Benefit Analysis RegistryThey also use the Tufts CEA Registry to assess the quality of CEA research.

Based on this method, the following conclusions are drawn:

  • Drug spending is highly concentrated. The top 30 drugs accounted for 33.5% of the total expenditure in Part D (48.9 billion US dollars), and the top 250 drugs accounted for 84.1% of the total expenditure (122.8 billion US dollars)
  • Endocrinology and Cardiology have the highest expenditure in Part DThe disease areas where medical insurance spends the most on Part D drugs are endocrinology ($23.3 billion), cardiology ($17.5 billion), and pulmonology ($12 billion). You will notice that Oncology is not on the list, in part because many oncology drugs are administered by clinicians and are therefore covered by Medicare Part B (not Part D).
  • Most drugs have undergone CEA studies, but many have not“Among the 250 drugs with the largest expenditures in Part D of Medicare, 135 (54.0%) were included in at least one cost-effectiveness study… Drugs with any evidence of cost-effectiveness accounted for 67.0% of the total expenditure on the top 250 drugs.”
  • Over time, the importance of CEA research has increasedAs shown in the figure below, the number of drugs undergoing CEA studies has increased over time.

Source link


Most Popular

Recent Comments